CME: Challenges and updates in the management of von Hippel-Lindau disease and related tumors
Activity Description / Statement of Need:
In this online, self-learning activity:
Von Hippel-Lindau (VHL) disease is a rare genetic condition caused by an autosomal dominant mutation of the VHL tumor suppressor gene. The mutation gives rise to an abnormal VHL protein that cannot bind effectively to protein HIF-1α, leading to the transcription of multiple genes and upregulation of growth factors. The condition is thought to affect between 1 in 39,000 and 1 in 91,000, with a birth incidence of between 1 in 36,000 and 1 in 45,500. Diagnosis of VHL disease is established when the patient undergoes genetic testing and a pathogenic mutation of the VHL gene is found. Genetic testing is typically conducted if the patient has a family history of VHL or they are showing signs of VHL-related symptoms. VHL disease is characterized by tumors and cysts growing in various parts of the body, including the brain, spine, eyes, inner ears, pancreas, kidneys, adrenal glands, and reproductive tract. The clinical presentation of the disease is different in every patient and is impossible to predict, so close monitoring is required. Complications of the disease are on a case-by-case basis, but patients with VHL are at an increased risk of developing some cancers, particularly clear cell renal cell carcinoma (RCC) and pancreatic cancer.
Target Audience:
HCPs including: Medical and genitourinary oncologists, urologists, and nephrologists; physician assistants, nurse practitioners, and pharmacists specializing in the aforementioned areas of specialty; and any other HCPs involved or interested in treatment of VHL disease.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
This activity is free of charge.
Release Date: September 08, 2023 -- Expiration Date: September 08, 2024
Faculty: Eric Jonasch, MD
Agenda
|
Faculty introduction and disclosures |
|
Introductory content and review of VHL disease and related tumors
|
|
Management of VHL disease and related tumors
|
|
Summary, conclusions, and best practice recap |
Learning Objectives
By the end of the session the participant will be able to:
- Summarize challenges to the healthcare burden, surveillance, and management of VHL and related tumors.
- Identify the currently available and emerging pharmacotherapeutic treatment options for the management of VHL-associated tumors and complications.
- Formulate a treatment plan for a patient with VHL disease-related tumors.
Accreditation
ACCME Activity #202548110
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through ScientiaCME. ScientiaCME is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation: ScientiaCME designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™ toward the AMA Physician's Recognition Award. Physicians should only claim credit commensurate with the extent of their participation in the activity.
ABIM MOC Recognition Statement: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
ABIM MOC Credit Type: Medical Knowledge
Physicians: For maintenance of certification (MOC) points, you must enter your board certification ID # and birth date correctly. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive MOC points for this activity. By providing this data, you acknowledge that it will be shared with ACCME and the applicable certifying board. Please note: Not all activities on this site provide MOC points. If this activity does not specify that it provides MOC points in this section, then it does NOT provide MOC points. This activity provides MOC points only for ABIM.
Pharmacists
ScientiaCME is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.75 contact hours (0.075 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit. ACPE #0574-0000-23-032-H01-P. This is an Application (A)-type activity.
Pharmacists: You must enter your NABP # and birth date correctly so that proof of participation can be posted to your NABP CPE profile. It is the learner's responsibility to provide this information completely and accurately at the completion of the activity. Without providing it, the learner will NOT receive CPE credit for this activity.
Nurses: The American Nurses Credentialing Center (ANCC) accepts AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.
Physician Assistants: The American Academy of Physician Assistants (AAPA) accepts AMA PRA Category 1 Credit™ assigned by organizations accredited by the ACCME as satisfying Category 1 CME for National Commission on Certification of Physician Assistants (NCCPA) national certification maintenance. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.
Nurse Practitioners: The American Academy of Nurse Practitioners Certification Board (AANPCB) states that continuing education providers accredited by the ACCME may provide acceptable, accredited Advanced Practice Provider content. This activity is designated for up to 0.75 AMA PRA Category 1 Credit(s)™.
Faculty Disclosure and Resolution of COI
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review by ScientiaCME.
Disclosures of Faculty: Eric Jonasch, MD, Professor, Department of Genitourinary Medical Oncology, University of Texas MD Anderson Cancer Center, has received financial compensation from Aveo, Arrowhead, Corvus, DAVA, Eisai, Exelixis, GSK, Ipsen, Merck, NiKang, Novartis, Takeda and Telix for research and/or consulting work.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP, President of ScientiaCME, has no relevant financial disclosures.
Faculty WILL discuss off-label uses of a commercial product.
All relevant financial relationships have been mitigated.
ScientiaCME adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.
Commercial Support Disclosure: This program is supported by an educational grant from Merck.
Instructions
- Read the learning objectives above
- Take the Pre-Test (optional). Completion of the pre-test will help us evaluate the knowledge gained by participating in this CME activity.
- View the online activity. You may view this is in more than one session, and may pause or repeat any portion of the presentation if you need to.
- Minimum participation threshold: Take the post-test. A score of 70% or higher is required to pass and proceed to the activity evaluation.
- Complete the activity evaluation and CME registration. A CE certificate will be emailed to you immediately.
System Requirements
Windows 7 or above
Internet Explorer 8
*Adobe Acrobat Reader
Mac OS 10.2.8
Safari or Chrome or Firefox
*Adobe Acrobat Reader
Internet Explorer is not supported on the Macintosh
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.
Additional Courses That Are Related To This Activity
Contemporary treatment approaches in the management of graft-versus-host disease (GVHD)
Prediction and management of bone complications in prostate cancer
Atypical hemolytic uremic syndrome (aHUS): best practices and effective management